Therapeutic Response

v::ROS1 status confers therapeutic sensitivity to Taletrectinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Ibtrozi (taletrectinib) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. The package insert instructs to select patients based on the presence of ROS1 rearrangements in tumor specimen(s).